Core Viewpoint - Karyopharm Therapeutics Inc. has announced a private placement with RA Capital Management, expected to generate approximately $30 million in gross proceeds, with potential additional proceeds of about $44 million if accompanying warrants are fully exercised [1][2]. Group 1: Private Placement Details - The company will sell 1,030,354 shares of common stock at $6.785 per share and 3,391,164 pre-funded warrants at $6.7849 each, along with warrants to purchase 4,421,518 shares of common stock at an exercise price of $10.00 per share [2]. - The pre-funded warrants will have an exercise price of $0.0001, will be immediately exercisable, and will not expire [2]. - The accompanying warrants will also be immediately exercisable and will expire 30 days after the public announcement of topline results from the Phase 3 XPORT-EC-042 clinical trial of selinexor in endometrial cancer patients [2]. Group 2: Financial Implications - The private placement is expected to close around March 26, 2026, pending customary closing conditions, and was priced at-the-market under Nasdaq rules [3]. - The net proceeds, along with existing liquidity and cash flow from product revenue, are anticipated to fund the company's operating plans into late Q3 2026 [3]. Group 3: Use of Proceeds - Proceeds from the private placement will be used for general corporate purposes, including ongoing and planned clinical trial activities [4]. Group 4: Company Overview - Karyopharm Therapeutics is a commercial-stage pharmaceutical company focused on developing novel cancer therapies, particularly oral compounds that address nuclear export dysregulation [7]. - The company's lead product, XPOVIO® (selinexor), is approved in the U.S. and marketed in three oncology indications, with regulatory approvals in 50 territories, including the EU, UK, and China [7]. - Karyopharm has a pipeline targeting multiple high unmet need cancers, including multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma [7].

Core Points - Karyopharm Therapeutics Inc. will report its second quarter 2025 financial results on August 11, 2025, at 8:00 a.m. ET [1] - A conference call and audio webcast will be hosted by the management team to discuss the financial results and company updates [1] Company Overview - Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company focused on pioneering novel cancer therapies, particularly oral compounds that address nuclear export dysregulation [3] - The company's lead compound, XPOVIO® (selinexor), is an oral exportin 1 (XPO1) inhibitor approved in the U.S. for three oncology indications and has received regulatory approvals in various international markets, including Europe and China [3] - Karyopharm has a focused pipeline targeting high unmet need cancers, including multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL) [3]

Core Viewpoint - Karyopharm Therapeutics Inc. is set to report its first quarter 2025 financial results on May 12, 2025, and will host a conference call to discuss these results and other updates [1]. Company Overview - Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company focused on pioneering novel cancer therapies, particularly through oral compounds that address nuclear export dysregulation, a key mechanism in cancer development [3]. - The company's lead product, XPOVIO® (selinexor), is an oral exportin 1 (XPO1) inhibitor that has received approval in the U.S. for three oncology indications and has also been approved in various international markets, including Europe and China [3]. - Karyopharm has a focused pipeline targeting multiple high unmet need cancers, including multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL) [3].